"Menopause costs American women an estimated $1.8 billion in lost working time per year, according to a Mayo Clinic study published this week. The paper examined how hot flashes, night sweats, mood swings and the myriad other symptoms associated with this time of life affect women in the workplace. It’s the largest study of its kind to have been done in the United States."
Whoa. Let’s get back to rationale discussions in brain research:
Debate is vital … The discussion that followed … this is a shame ….
https://www.thelancet.com/pdfs/journals/lanpsy/PIIS2215-0366(14)70363-3.pdf
'Writing in Nature, Krishna et al.2 show that malignant gliomas can grow by modifying brain circuitry, thus taking cognitive function away from their host and ultimately leading to death. These insights might lead to fundamentally new approaches to glioma treatment and provide a means of limiting cognitive decline in affected individuals.'
'We demonstrate that while male NK cells display enhanced cellular fitness in mice, they show decreased effector function in mice and humans. These sex biases in NK cell composition and function were not completely due to hormonal differences, because they persisted in gonadectomized mice'
2. There is a very honest description of scientists' motivations. We are all "epistemically sullied", motivated by both curiosity AND desire for recognition.
It is critical to acknowledge this as we seek to reenvisage publishing. Denying the fact (how it drives pursuit of JIF, CNS, h index, competition, etc.) won't help us. The key is to understand this and then think how the system can be improved so distortions (Goodhart's Law, etc.) are minimized.
3/3
This is exciting:
"...In this Article, we show that gut-specific telomerase expression in tert−/− zebrafish is sufficient to delay gut aging. Counteracting gut aging improves health of the entire organism, reverting gut microbiota dysbiosis and aging phenotypes in distant organs of tert−/− zebrafish"
https://rdcu.be/dbo2E
Interplay Between Polymorphic Short Tandem Repeats and Gene Expression Variation in Caenorhabditis elegans https://doi.org/10.1093/molbev/msad067 #science #evolution #biology #genome #SciComm #evolgen_paper
"A "very concerning" rise in the number of people catching measles in the UK has been reported by health officials.
The virus spreads incredibly easily and a fall in vaccination rates is leaving more children vulnerable."
Get Vaccinated.
#VaccinesWork
https://www.bbc.co.uk/news/health-65481976
1. There's a great explanation of the oft-cited Why Most Published Research Findings are False paper by John Ioannidis that explains why assumptions made about how scientists general hypotheses mean this is not correct.
Others have pointed this out but Carl and Jevin give a very clear explanation of why, which is important given how frequently and uncritically this work is cited in our sphere 2/3
Calling Bullshit by @ct_bergstrom is a fascinating read that brilliantly summarizes issues around data interpretation, various logical fallacies, phony graphs, and misleading statistics.
That alone makes it essential reading but two other things stood out for me that may interest sci comm/publishing types. 1/3
90% of cancers reactivate telomerase. In our new preprint, we reveal that tumors that fail to activate telomerase trigger a stronger immune response, leading to melanoma regression. Our work also sheds light on the association between telomerase gene mutations and the immune system and provide a mechanism to explore the success of immunotherapies.
🐟 #zebrafish 🧬#telomerase 💊#immunotherapy 🔬#cancerresearch https://www.biorxiv.org/content/10.1101/2023.03.24.534079v1
'But Eli Lilly’s preliminary donanemab results also reveal a sobering risk of brain swelling and hemorrhaging, side effects that the company disclosed may be linked to two—perhaps three—deaths in the clinical trial and that echo hazards seen with lecanemab, which is being marketed by Eisai and Biogen.'
💥learn science from one of the best💥
---
RT @HarmitMalik
We have 2 res. tech. openings in our lab starting soon. Please RT & bring this to the attention of students interested in getting hands-on experience in the lab before heading to grad/ med school. We value curiosity, mentorship, & diversity.
1st position: https://jobrxiv.org/job/research-technician-i-malik-lab/
https://twitter.com/HarmitMalik/status/1654238564752973824
Out now! 👇Over a century ago, Elie Metchnikov proposed that #aging is caused by increasing #intestine permeability and toxic #microbiota into our bodies. In our last paper provides evidence for this idea and a potential mechanism for “inflammaging”. #IRCAN #IGC #CNRS #zebrafish 🐟 https://doi.org/10.1038/s43587-023-00401-5
'A recent American study found that an elite class of principal investigators who hold three or more concurrent NIH (National Institutes of Health) grants grew in number over the past 30 years but, even after controlling for career stage and degree, women were significantly underrepresented. And despite evidence of diminishing returns for annual grants over US$600,000, the dollars remain concentrated in the hands of a select few.'
'For patients in a late-stage trial, the drug called donanemab slowed progression of the disease by 35 per cent compared with those who took the placebo during an 18-month treatment period. The decline in patients’ ability to perform daily tasks was 40 per cent lower for those on the drug.
However, the drug displayed severe side effects such as brain swelling and bleeding and three people on the trial died.'
#alzheimers #alzheimersdisease
https://www.ft.com/content/11a59576-e057-433a-b1f9-393159bda85c
UKHSA is doing a study to try to map out immunity to #mpox. It had been assumed mpox was a one-and-done type of infection, but there have been a few reports of what looks like repeat infections, like this recent paper in Lancet. https://www.thelancet.com/action/showPdf?pii=S1473-3099%2823%2900185-8 and https://www.gov.uk/government/news/study-launched-to-find-out-more-about-mpox-immunity
'For patients in a late-stage trial, the drug called donanemab slowed progression of the disease by 35 per cent compared with those who took the placebo during an 18-month treatment period. The decline in patients’ ability to perform daily tasks was 40 per cent lower for those on the drug.
However, the drug displayed severe side effects such as brain swelling and bleeding and three people on the trial died.'
#alzheimers #alzheimersdisease
https://www.ft.com/content/11a59576-e057-433a-b1f9-393159bda85c
I've worked on all of science, from B cells to T cells.
https://fellowsherpa.com